A global, culturally connected team of professionals with deep experience and a proven track record in all elements of the
pharmaceutical business.
We are a fully aligned plug and play network of subject matter experts and organisations who find, qualify and direct all or some of the elements you need to complete your deals or programs.
A World-Class Advisory Board with Decades of Expertise
Our Advisory Board brings over 35 years of cross-pharmaceutical and global business experience, offering strategic guidance and industry-leading insights. Comprised of top experts from around the world, our board ensures that every decision is backed by deep industry knowledge, innovative thinking, and a commitment to excellence. With a proven track record in pharmaceutical development, regulatory strategy, and business growth, our advisors play a crucial role in shaping the future of healthcare. Their expertise drives smarter solutions, accelerates innovation, and strengthens our global impact.
Management Board
Our management team brings over 160 years of combined experience in the pharmaceutical industry and is known as the enabling force behind our operations
-
Russell Spencer
FounderRussell has more than 30 years technical and commercial global Pharmaceutical experience in Rx, Gx and FMCG. He founded the VPA to provide PE/VC, Pharmaceutical companies, CRDMO’s and Suppliers an agile and flexible partner to support deals, develop portfolios and products. To provide consultancy across all aspects of the business and then execute programs with the same team and build supply chains and value streams as needed. Using its extensive and trusted network the VPA can leverage its experience for you and manage as much or as little of strategies or product developments as you want. The VPA’s motto “Delight, Deliver, Depart”™
-
Olga Urazova
ProgramOlga is a senior Executive with over 20 years global experience in Pharmaceuticals leading organisational transformation as well as building world-class Commercial, Business Development and Procurement strategies. She has directed development and commercialisation of API's, C(R)DMO API's, FDF requirements and relationships, Procurement, Supply Chain, Portfolio Planning, Project Management, Pipeline Development, Market Intelligence and Alliance Management. Passionate in driving talent development, inclusion & diversity and driven by a deep passion for making a positive impact on the world.
-
Andy Burgess
Science – Small MoleculeAndy has over 35 years experience, Glaxo, GlaxoWellcome, GSK, Mylan and Independent Consultant. He has covered a broad range of roles in R&D and Operations from analytical and formulation including leading teams specialising in physical properties of API’s and Lactose for Respiratory Products through and CMC sections for analytical and formulation on respiratory products, working on every powder inhaler GSK has commercialised, as well as pMDI’s, INS and OSD. In addition, he has nearly 18 years strategic sourcing and business development experience, leveraging his scientific knowledge creating robust win-win value streams.
-
Gary Parson
Science – Large MoleculeGary has over 30 years experience in medicine design, development and supply across large and small molecules through a career with major Pharma. Gary has held leadership roles at all stages of technical development and commercial supply. He played a key role in the creation of GSKs Ellipta portfolio of products, from inception to launch and industrialisation. He believes strongly in the value of formulation design and has a track record of technical innovation successfully advancing medicines to the market rapidly.
-
Tommaso Pacini
IP & PortfolioTommaso has more than 12 years experience in forensic, environmental, and pharmaceutical chemistry, he strives to foster a greener, fairer, and safer scientific landscape. Through research in pesticides and mycotoxins, consultancy in tribunals, intellectual property management and portfolio strategy, promoting sustainability, justice, and public health. As co-founder of an eco-focused initiative, he advocates for responsible innovation while championing accurate scientific communication to combat misinformation and ensure knowledge serves both people and the planet.
-
Chris Vernall
BusinessChris is a consultant specializing in respiratory drug development and business strategy. He is the Executive VP of Business Development at HCmed Innovations, supporting inhaled medicine development for partners globally. With a background in chemistry, he holds master’s degrees from Loughborough University and Imperial College Business School. His career began at Nanopharm in 2010, followed by roles at Intertek, Aptar Pharma, and Vectura. Passionate about inhaled drug product development, he previously established the Inhaled and Nasal Biologics Forum and has led working groups in the IPAC-RS consortium. He specialises in linking technical and commercial strategies and spotting opportunities for collaboration.
Principals
Our Principals, each with over 20 years of experience in delivering complex programs, embody our commitment to expertise, precision and innovation. Their extensive background ensures that we consistently provide strategic guidance and hands-on leadership, driving impactful solutions for our clients
